Recorded an extraordinary loss of 290 million yen due to a decline in the market value of investment securities in the Q4 consolidated accounting period of the fiscal year ending December 2025, reflected in the financial summary.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3902","jir_company_name":"Medical Data Vision Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-02-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/3902-20260209-01.pdf","jir_short_summary":"Recorded an extraordinary loss of 290 million yen due to a decline in the market value of investment securities in the Q4 consolidated accounting period of the fiscal year ending December 2025, reflected in the financial summary.","jir_summary":"### Regarding Recording of Extraordinary Loss\nMedical Data Vision Co., Ltd. recorded an impairment loss of 290 million yen as an extraordinary loss for the Q4 consolidated accounting period of the fiscal year ending December 2025 due to a significant decline in the market value or intrinsic value of certain investment securities held, compared to their acquisition cost.\n\n### Impact on Financial Results\nThis extraordinary loss is reflected in the \"Financial Summary for the Fiscal Year Ending December 2025 [Japanese GAAP] (Consolidated)\" announced on the same day, and impacts the financial results; however, the specific impact amount and effect on net income are unknown.","jir_financial_highlights":"Extraordinary Loss (Impairment Loss on Investment Securities): 290 million yen (Unknown)","jir_category":"","jir_hashtags":"#MedicalDataVision, #ExtraordinaryLoss, #FinancialSummary","jir_key_figures":"Extraordinary Loss (Impairment Loss on Investment Securities): 290 million yen\nApplicable Period: Q4 consolidated accounting period for the fiscal year ending December 2025\nFinancial Summary Reflection Date: 2026-02-09","jir_meta_title":"Medical Data Vision Records 290 Million Yen Impairment Loss on Investment Securities in Fiscal Year Ending December 2025","jir_meta_description":"Medical Data Vision Co., Ltd. recorded an extraordinary loss of 290 million yen due to a decline in investment securities' market value in the Q4 of fiscal year ending December 2025, reflected in the financial summary.","jir_og_title":"Medical Data Vision Announces Recording of 290 Million Yen Extraordinary Loss","jir_og_description":"Recorded an impairment loss of 290 million yen on investment securities in Q4 of fiscal year ending December 2025, reflected in the financial summary.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":17052,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-26027","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n